Table 3.
Univariate analysis of local control for metastases treated with GK SRS.
| Factor | N | # events | Local control at 1 year (%) | Median months to failure | Relative risk of failure (95% CI) | p-value |
|---|---|---|---|---|---|---|
| Overall | 69 | 26 | 49 | 7.7 | ||
| BRAF | 0.01 | |||||
| Wild-type | 39 | 19 | 34 | 4.5 | 1.0 | |
| Mutated | 30 | 7 | 69 | 5.6 | 0.3 (0.1–0.7) | |
| WBRT | 0.19 | |||||
| No | 25 | 7 | 65 | 2.7 | 1.0 | |
| Yes | 44 | 19 | 40 | 6.2 | 1.9 (0.7–5.2) | |
| Treatment volume (ml) | 0.83 | |||||
| <1.0 | 34 | 14 | 52 | 7.4 | 1.0 | |
| ≥1.0 | 35 | 12 | 44 | 4.5 | 1.1 (0.5–2.5) | |
| Max tumor dimension (cm) | 0.46 | |||||
| <0.80 | 29 | 16 | 55 | 7.6 | 1.0 | |
| ≥0.80 | 40 | 10 | 45 | 4.5 | 1.4 (0.6–3.2) | |
| Marginal dose | 0.03 | |||||
| <22 Gy | 30 | 16 | 27 | 5.3 | 1.0 | |
| ≥22 Gy | 39 | 10 | 67 | 3.9 | 0.4 (0.2–0.9) |